Articles which will keep customers informed of any updates and changes to the system that they need to be aware of.
BNF Code Changes January 2021
The annual BNF version changes are due to be implemented with January 2021 dispensing data, planned publication of this data is around mid-March 2021.
The latest published mapping file shows the BNF presentation code as of December 2020 data against the BNF presentation code as of January 2021 data, also included is the BNF presentation name.
As ePACT2 always uses the latest BNF code, the BNF code as of January 2021 onwards will also apply to all historical data.
For any static reports, example monthly PCA data, English Prescribing Data (EDP) the BNF presentation code prior to January 2021 data will remain unchanged.
Amended 2020 to 2021 forecast out-turn profile now available
The amended forecast out-turn 2020 to 2021 will be made available with reports released in February 2021 relating to December 2020 prescribing. The profile takes into account the CAT M changes in October 2020 and January 2021.
An amended forecast template has also been made available on the financial forecasting webpage.
ePACT2 Sandbox - New ideas, quicker feedback
We have created an area within ePACT2 called the ‘Sandbox’ where we will be encouraging users to test, check and feedback on beta versions of new reports, dashboards and features that are under development.
We want to engage with you and for you to be involved earlier in the process when we are working on ideas and this Sandbox area lets us get new features and releases to you quickly.
We will listen to and collate your feedback and then decide if the idea progresses into the main ePACT2 system or if it should be re-designed or even scrapped.
The Sandbox area can be found on the landing page as you enter ePACT2.
One Drug Database mapping documents
The following documents only contain presentations prescribed from January 2014 – November 2019. Presentations not prescribed within this time will not be included.
Diabetes Dashboard update
The following metrics have changed:
- Metric 1: number of unique patients prescribed Blood Glucose Testing Strips with any non-insulin blood glucose lowering therapies and not prescribed insulin.
- Metric 2: number of unique patients prescribed Blood Glucose Testing Strips with Metformin but no insulin.
- Metric 3: number of unique patients prescribed Blood Glucose Testing Strips with any non-insulin blood glucose-lowering therapy and insulin.
Previously, the metrics included patients who were not prescribed blood glucose testing strips, as well as those who were.
This has been changed to include only patients who were prescribed testing strips, and match the rest of the prescribing combination for the metrics:
- Metric 1: number of unique patients prescribed Blood Glucose Testing Strips and any non-insulin blood glucose-lowering therapies and not prescribed insulin.
- Metric 2: number of unique patients prescribed Blood Glucose Testing Strips and Metformin but no insulin.
- Metric 3: number of unique patients prescribed Blood Glucose Testing Strips and any non-insulin blood glucose-lowering therapy AND insulin.
This will have an impact on figures, removing approximately 85% of patients from metrics 1 and 2, and 25% of patients from metric 3 nationally.
The change has been made because the focus of the metrics is on the use of testing strips. It's important to make sure that only patients prescribed the testing strips are included.
This change will affect all three graphics for these metrics, for all organisation levels.
One Drug Database
For many years we had 2 sources of drug data. These were Master Data Replacement (MDR) and Common Drug Reference (CDR).
The MDR database is used for reporting purposes whilst the CDR database is used for the transactional processing of prescription items.
There are inconsistencies in how the data is stored in each of the databases which can cause confusion, especially as different naming conventions are used in both systems.
We're running a project to improve this situation by migrating all drug usage to CDR and decommissioning the MDR Drug system completely.
Moving to one source of drug information will save the effort of maintaining 2 sets of drug records and improve quality by making sure all of our applications, and external customers of drug data, are using a single and consistent source of drug data.
Delivering these benefits directly contributes to our strategic goals, which are to generate efficiency across health and social care system, make things easy for our customers through the delivery of brilliant basics, and to collaborate to maximise the return on data to improve health outcomes for patients.
The project is underway and will hopefully be completed by the end of this calendar year, where all drug data which is currently held only in MDR will be migrated to CDR which will then be the one single data source.
We'll continue to keep you updated with our progress on this.